Merck’s Estimates Boosted at UBS; Sees Victrelis as a Catalyst (MRK)


Shutterstock photo

Drugmaker Merck & Co., Inc. ( MRK ) on Thursday saw its earnings estimates boosted by analysts at UBS, based on the introduction of its new hepatitis C treatment, Victrelis.

The firm said it raised its estimates for MRK through 2011, while maintaining its "Buy" rating and $42 price target. That target suggests a healthy 18% upside to the stock's Wednesday closing price of $35.53.

Merck shares were mostly flat in premarket trading Thursday.

The Bottom Line
Shares of Merck ( MRK ) have a 4.28% dividend yield, based on last night's closing stock price of $25.53. The stock has technical support in the $32 price area. If the shares can firm up, we see overhead resistance around the $37-$38 price levels.

Merck & Co., Inc. ( MRK ) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by

This article appears in: Investing , Stocks

More from

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by